This review aimed to focus on the pathophysiology and management of patent ductus arteriosus and to make suggestions about approaches that might eliminate the association of morbidities with patent ductus arteriosus.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Patent ductus arteriosus is the most common cardiovascular condition in preterm infants.
📊
Key Findings & Data:There is a significant uncertainty about when and how to close ductus arteriosus in preterm infants due to a high spontaneous closure rate even in very immature preterm infants.
💡
Conclusion & Impact:This review aimed to focus on the pathophysiology and management of patent ductus arteriosus and to make suggestions about approaches that might eliminate the association of morbidities with patent ductus arteriosus.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Patent ductus arteriosus is the most common cardiovascular condition in preterm infants. There is a significant uncertainty about when and how to close ductus arteriosus in preterm infants due to a high spontaneous closure rate even in very immature preterm infants. Diagnosis and management of patent ductus arteriosus remain a challenge for both neonatologists and pedi- atric cardiologists. Researchers have tried to define a balance between an expectant approach and active treatment in selected infants. This review aimed to focus on the pathophysiology and management of patent ductus arteriosus and to make suggestions about approaches that might eliminate the association of morbidities with patent ductus arteriosus.
🔖
Cite This Article
ERDEVE, Ö., OKULU, E., SİNGH, Y., SİNDELAR, R., ONCEL, M. Y., TERRİN, G., BOSCARİNO, G., BÜLBÜL, A., SALLMON, H., ATASAY, B., OVALI, F., CLYMAN, R. I. (2022). An Update on Patent Ductus Arteriosus and What is Coming Next. Turkish archives of pediatrics (Online), Cilt: 57 - Sayı: 2, 118–131. https://ajindex.com/articles/418264
Atasay B, Erdeve Ö, Sallmon H, Singh Y [editorial]. Editorial: Man- agement of patent ductus arteriosus in preterm infants. Front Pediatr. 2021
681393. [CrossRef] 2. Okulu E, Erdeve O, Arslan Z, et al. An observational, prospective, multicenter, registry-based cohort study comparing conservative and medical management for patent ductus arteriosus. Front Pediatr. 2020
[CrossRef] 3. Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate- to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019
e6. [CrossRef] 4. Smith A, El-Khuffash A. Patent ductus arteriosus clinical trials: les- sons learned and future directions. Children (Basel, Switzerland). 2021
8(1):47. [CrossRef] 5. Reese J. Towards a greater understanding of the ductus arteriosus. Semin Perinatol. 2018
42(4):199-202. [CrossRef] 6. Ovalı F. Molecular and mechanical mechanisms regulating ductus arteriosus closure in preterm infants. Front Pediatr. 2020
[CrossRef] 7. Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol. 2004
19(7). [CrossRef] 9. Hu Y, Jin H, Jiang Y, Du J. Prediction of therapeutic response to cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus. Pediatr Cardiol. 2018
39(4):647-652. [CrossRef] 10. Echtler K, Stark K, Lorenz M, et al. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med. 2010
16(1):75-82. [CrossRef] 11. Hamrick SEG, Sallmon H, Rose AT, et al. Patent ductus arteriosus of the preterm infant. Pediatrics. 2020
146(5). [CrossRef] 12. Sallmon H, Timme N, Atasay B, et al. Current controversy on plate- lets and patent ductus arteriosus closure in preterm infants. Front Pediatr. 2021
612242. [CrossRef 13. Sallmon H, Weber SC, Hüning B, et al. Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus. Pediatrics. 2012